Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Chemotherapy for Skull Base-Invading HNSCC
NCT07145931Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07145931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145931.